Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

385
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
385
G-protein Coupled Receptors01:21

G-protein Coupled Receptors

121.9K
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
121.9K
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

647
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
647
Depressive Disorders: Etiology01:27

Depressive Disorders: Etiology

175
Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
175
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

1.2K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.2K
Depression: Overview01:18

Depression: Overview

383
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
383

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dual-Branch Fusion Network: Precise Decoding of Lower Limb Multi-Joint Torque.

IEEE transactions on bio-medical engineering·2026
Same author

Atomic-scale mechanism unlocks thermal-stable high-κ performance in HfO<sub>2</sub> via coherent interfaces.

Nature communications·2026
Same author

Deficiency of extracellular vesicles miR-32 from bone marrow mesenchymal stem cells alleviates vascular calcification in type 2 diabetes by inhibiting endothelial ferroptosis.

Stem cell research & therapy·2026
Same author

Treadmill exercise alleviates Alzheimer's disease pathologies in APP/PS1 mice through modulation of microglial glucose metabolic reprogramming.

Frontiers in aging neuroscience·2026
Same author

Network pharmacology analysis and in vitro experimental validation of liriodenine against non-small cell lung cancer.

BMC cancer·2025
Same author

Pushing mid-infrared Ho<sup>3+</sup>-doped laser ceramics power-scaling at 3 µm by synergistic phonon energy reduction and ionic deactivation.

Optics express·2025

Related Experiment Video

Updated: Sep 23, 2025

The Forced Swim Test as a Model of Depressive-like Behavior
05:42

The Forced Swim Test as a Model of Depressive-like Behavior

Published on: March 2, 2015

37.9K

The Relationship Between 5-Hydroxytryptamine and Its Metabolite Changes With Post-stroke Depression.

Simeng Gu1,2, Zhengming He2, Qiuyue Xu3

  • 1Department of Psychology, Jiangsu University Medical School, Zhenjiang, China.

Frontiers in Psychiatry
|May 13, 2022
PubMed
Summary

Post-stroke depression (PSD) affects one-third of stroke survivors. This study explores the role of monoamines and proposes a new emotional model for PSD treatment and prevention.

Keywords:
5-Hydroxytryptamineemotional interventionmonoamine hypothesispost-stroke depressionthree primary emotions

More Related Videos

A Middle Cerebral Artery Occlusion Technique for Inducing Post-stroke Depression in Rats
04:38

A Middle Cerebral Artery Occlusion Technique for Inducing Post-stroke Depression in Rats

Published on: May 22, 2019

10.4K
A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
07:56

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

Published on: August 11, 2021

3.4K

Related Experiment Videos

Last Updated: Sep 23, 2025

The Forced Swim Test as a Model of Depressive-like Behavior
05:42

The Forced Swim Test as a Model of Depressive-like Behavior

Published on: March 2, 2015

37.9K
A Middle Cerebral Artery Occlusion Technique for Inducing Post-stroke Depression in Rats
04:38

A Middle Cerebral Artery Occlusion Technique for Inducing Post-stroke Depression in Rats

Published on: May 22, 2019

10.4K
A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
07:56

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

Published on: August 11, 2021

3.4K

Area of Science:

  • Neuroscience
  • Psychiatry
  • Clinical Medicine

Background:

  • Post-stroke depression (PSD) is a common and severe complication affecting approximately 33% of stroke survivors.
  • Despite its prevalence, key aspects of PSD, including incidence, diagnostic markers, and risk factors, remain poorly understood.
  • The established "monoamine hypothesis" guides current antidepressant treatments for PSD, but the precise mechanisms involving monoamines are still unclear.

Purpose of the Study:

  • To review current understanding of post-stroke depression (PSD) and its relationship with monoamines.
  • To introduce the novel "three primary emotions" model as a potential new framework for understanding and treating PSD.
  • To discuss the therapeutic potential of monoamine-related emotional interventions in PSD treatment and prevention.

Main Methods:

  • Literature review and synthesis of existing research on post-stroke depression.
  • Discussion of the "monoamine hypothesis" and its implications for PSD.
  • Introduction and exploration of the proposed "three primary emotions" model.

Main Results:

  • Current antidepressants targeting monoamines show efficacy in PSD, but underlying mechanisms require further elucidation.
  • The proposed "three primary emotions" model offers a new perspective on the neurobiological basis of emotions in PSD.
  • Emerging evidence suggests that emotional interventions targeting monoamine pathways may be beneficial for PSD.

Conclusions:

  • Further research is needed to clarify the incidence, diagnostic markers, and risk factors of PSD.
  • The "three primary emotions" model and monoamine-related interventions present promising avenues for future PSD research and treatment.
  • A deeper understanding of monoamine function in PSD could lead to more targeted and effective therapeutic strategies.